Feasibility of using pemetrexed as a salvage regimen in heavily pre-treated patients with ovarian cancer: A retrospective review

被引：1
|
作者：
Dottino, Peter [1 ]
Dashkoff, Matthew [1 ]
Beddoe, Ann Marie [1 ]
机构：
[1] Icahn Sch Med, Dept Obstet Gynecol & Reprod Sci, New York, NY 10029 USA
来源：
INDIAN JOURNAL OF CANCER | 2020年 / 57卷 / 04期
关键词：
SURVIVAL;
D O I：
10.4103/ijc.IJC_284_19
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：491 / 493
页数：3
相关论文
共 50 条
  • [31] Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer
    Takano, M
    Kikuchi, Y
    Kita, T
    Suzuki, M
    Ohwada, M
    Yamamoto, T
    Yamamoto, K
    Inoue, H
    Shimizu, K
    ANTICANCER RESEARCH, 2002, 22 (03) : 1833 - 1838
  • [32] USE OF NovoTTF-100A™ IN HEAVILY PRE-TREATED PATIENTS WITH RELAPSED HIGH GRADE GLIOMA: A RETROSPECTIVE CHART REVIEW
    Sumrall, Ashley
    Haggstrom, Daniel
    Crimaldi, Anthony
    Symanowski, James
    Giglio, Pierre
    Asher, Anthony
    Burri, Stuart
    NEURO-ONCOLOGY, 2013, 15 : 83 - 83
  • [33] Increased survival for heavily pre-treated metastatic breast cancer
    Siddall, Rhonda
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2010, 71 (07) : 370 - 370
  • [34] Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients
    Musto, Pellegrino
    Fraticelli, Vincenzo Ludovico
    Mansueto, Giovanna
    D'Arena, Giovanni
    Petrilli, Maria Pia
    Gasbarrino, Cristiana
    Farina, Giuliana
    Guariglia, Roberto
    Martorelli, Maria Carmen
    Villani, Oreste
    Pietrantuono, Giuseppe
    Catalano, Lucio
    Madonna, Emanuela
    Nozza, Andrea
    Andriani, Alessandro
    Montefusco, Vittorio
    Mussetti, Alberto
    Lipari, Maria Grazia
    Ballanti, Stelvio
    Bongarzoni, Velia
    Tamiazzo, Stefania
    Patriarca, Francesca
    Vincelli, Donatella
    Falcone, Antonietta
    Derudas, Daniele
    Califano, Catello
    Zambello, Renato
    Mele, Giuseppe
    Fragasso, Alberto
    Baldini, Luca
    Palumbo, Antonio
    Storti, Sergio
    BLOOD, 2012, 120 (21)
  • [35] Cyberknife SBRT for liver metastases in heavily pre-treated patients
    Martenka, P.
    Skrobala, A.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S563 - S563
  • [36] Prognostic and predictive factors of eribulin in patients with heavily pre-treated metastatic breast cancer
    Chen, Pei-Hsin
    Yeh, Dah-Cherng
    Tung, Heng-Hsin
    Lin, Chin-Yao
    MEDICINE, 2021, 100 (47)
  • [37] Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
    Ferrandina, Gabriella
    Corrado, Giacomo
    Mascilini, Floriana
    Malaguti, Paola
    Samaritani, Riccardo
    Distefano, Mariagrazia
    Masciullo, Valeria
    Di Legge, Alessia
    Savarese, Antonella
    Scambia, Giovanni
    BMC CANCER, 2014, 14
  • [38] Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study
    Gabriella Ferrandina
    Giacomo Corrado
    Floriana Mascilini
    Paola Malaguti
    Riccardo Samaritani
    Mariagrazia Distefano
    Valeria Masciullo
    Alessia Di Legge
    Antonella Savarese
    Giovanni Scambia
    BMC Cancer, 14
  • [39] Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer
    Qvortrup, Camilla
    Jensen, Benny Vittrup
    Jorgensen, Trine Lembrecht
    Nielsen, Dorte
    Bjerregaard, Jon Kroll
    Pfeiffer, Per
    ACTA ONCOLOGICA, 2010, 49 (06) : 833 - 836
  • [40] Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer
    Andrikopoulou, Angeliki
    Liontos, Michalis
    Skafida, Efthymia
    Koutsoukos, Konstantinos
    Apostolidou, Kleoniki
    Kaparelou, Maria
    Rouvalis, Angeliki
    Bletsa, Garyfallia
    Dimopoulos, Meletios-Athanasios
    Zagouri, Flora
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (04) : 571 - 576
12345